{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T17:34:25Z","timestamp":1790876065335,"version":"4.1.0"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,6,2]]},"DOI":"10.7759\/cureus.85219","type":"journal-article","created":{"date-parts":[[2025,6,2]],"date-time":"2025-06-02T08:54:20Z","timestamp":1748854460000},"source":"Crossref","is-referenced-by-count":2,"title":["Efficacy and Safety of Once-Weekly Trelagliptin As Compared to Twice-Daily Vildagliptin in Indian Patients With Type 2 Diabetes Mellitus: A Randomized, Phase 3, Non-inferiority Clinical Trial"],"prefix":"10.7759","author":[{"given":"Bhupesh","family":"Dewan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siddheshwar","family":"Shinde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shefali","family":"Roy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","unstructured":"International diabetes federation. IDF Diabetes Atlas 11th edition. (2025). Accessed. May 26, 2025: https:\/\/idf.org\/about-diabetes\/diabetes-facts-figures\/."},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(23)00119-5","article-title":"ICMR-INDIAB Collaborative Study Group: Metabolic non-communicable disease health report of India: The ICMR-INDIAB national cross-sectional study (ICMR-INDIAB-17)","volume":"11","author":"Anjana RM","year":"2023","unstructured":"Anjana RM, Unnikrishnan R, Deepa M, et al..  ICMR-INDIAB Collaborative Study Group: Metabolic non-communicable disease health report of India: The ICMR-INDIAB national cross-sectional study (ICMR-INDIAB-17). Lancet Diabetes Endocrinol. 2023, 11:474-89. 10.1016\/S2213-8587(23)00119-5","journal-title":"Lancet Diabetes Endocrinol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/S2214-109X 30387-5","article-title":"The increasing burden of diabetes and variations among the states of India: The Global Burden of Disease Study 1990-2016","volume":"6","author":"Tandon N","year":"2018","unstructured":"Tandon N, Anjana RM, Mohan V, et al.. The increasing burden of diabetes and variations among the states of India: The Global Burden of Disease Study 1990-2016. Lancet Glob Health. 2018, 6:e1352-62. 10.1016\/S2214-109X 30387-5","journal-title":"Lancet Glob Health"},{"key":"ref4","unstructured":"International Diabetes Federation. IDF Diabetes Atlas. 10th edition. (2021). Accessed. February 22, 2025: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK581934\/."},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-023-29978-y","article-title":"Socioeconomic inequality in awareness, treatment and control of diabetes among adults in India: Evidence from National Family Health Survey of India (NFHS), 2019-2021","volume":"13","author":"Maiti S","year":"2023","unstructured":"Maiti S, Akhtar S, Upadhyay AK, Mohanty SK. Socioeconomic inequality in awareness, treatment and control of diabetes among adults in India: Evidence from National Family Health Survey of India (NFHS), 2019-2021. Sci Rep. 2023, 13:2971. 10.1038\/s41598-023-29978-y","journal-title":"Sci Rep"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1517\/14656566.2015.1099630","article-title":"First novel once-weekly DPP-4 inhibitor, trelagliptin, for the treatment of type 2 diabetes mellitus","volume":"16","author":"Kaku K","year":"2015","unstructured":"Kaku K. First novel once-weekly DPP-4 inhibitor, trelagliptin, for the treatment of type 2 diabetes mellitus. Expert Opin Pharmacother. 2015, 16:2539-47. 10.1517\/14656566.2015.1099630","journal-title":"Expert Opin Pharmacother"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-014-0166-0","article-title":"Retrospective study of adherence to glucagon-like peptide-1 receptor agonist therapy in patients with type 2 diabetes mellitus in the United States","volume":"31","author":"Johnston SS","year":"2014","unstructured":"Johnston SS, Nguyen H, Felber E, Cappell K, Nelson JK, Chu BC, Kalsekar I. Retrospective study of adherence to glucagon-like peptide-1 receptor agonist therapy in patients with type 2 diabetes mellitus in the United States. Adv Ther. 2014, 31:1119-33. 10.1007\/s12325-014-0166-0","journal-title":"Adv Ther"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.27.12.2800","article-title":"Clinical outcomes and adherence to medications measured by claims data in patients with diabetes","volume":"27","author":"Pladevall M","year":"2004","unstructured":"Pladevall M, Williams LK, Potts LA, Divine G, Xi H, Lafata JE. Clinical outcomes and adherence to medications measured by claims data in patients with diabetes. Diabetes Care. 2004, 27:2800-5. 10.2337\/diacare.27.12.2800","journal-title":"Diabetes Care"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1007\/s13300-013-0034-y","article-title":"Adherence to therapies in patients with type 2 diabetes","volume":"4","author":"Garc\u00eda-P\u00e9rez LE","year":"2013","unstructured":"Garc\u00eda-P\u00e9rez LE, Alvarez M, Dilla T, Gil-Guill\u00e9n V, Orozco-Beltr\u00e1n D. Adherence to therapies in patients with type 2 diabetes. Diabetes Ther. 2013, 4:175-94. 10.1007\/s13300-013-0034-y","journal-title":"Diabetes Ther"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.2169\/internalmedicine.8184-16","article-title":"Efficacy and patient satisfaction of the weekly DPP-4 inhibitors Trelagliptin and omarigliptin in 80 Japanese patients with type 2 diabetes","volume":"56","author":"Tosaki T","year":"2017","unstructured":"Tosaki T, Kamiya H, Yamamoto Y, et al.. Efficacy and patient satisfaction of the weekly DPP-4 inhibitors Trelagliptin and omarigliptin in 80 Japanese patients with type 2 diabetes. Intern Med. 2017, 56:2563-9. 10.2169\/internalmedicine.8184-16","journal-title":"Intern Med"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1507\/endocrj.EJ17-0303","article-title":"Satisfaction and efficacy of switching from daily dipeptidyl peptidase-4 inhibitors to weekly trelagliptin in patients with type 2 diabetes-Randomized controlled study","volume":"65","author":"Oita M","year":"2018","unstructured":"Oita M, Miyoshi H, Ono K, et al.. Satisfaction and efficacy of switching from daily dipeptidyl peptidase-4 inhibitors to weekly trelagliptin in patients with type 2 diabetes-Randomized controlled study. Endocr J. 2018, 65:141-50. 10.1507\/endocrj.EJ17-0303","journal-title":"Endocr J"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-015-0431-9","article-title":"Trelagliptin: First Global Approval","volume":"75","author":"McKeage K","year":"2015","unstructured":"McKeage K. Trelagliptin: First Global Approval. Drugs. 2015, 75:1161-4. 10.1007\/s40265-015-0431-9","journal-title":"Drugs"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-019-01097-z","article-title":"A randomized pilot study of the effect of Trelagliptin and Alogliptin on glycemic variability in patients with type 2 diabetes","volume":"36","author":"Nishimura R","year":"2019","unstructured":"Nishimura R, Osonoi T, Koike Y, Miyata K, Shimasaki Y. A randomized pilot study of the effect of Trelagliptin and Alogliptin on glycemic variability in patients with type 2 diabetes. Adv Ther. 2019, 36:3096-109. 10.1007\/s12325-019-01097-z","journal-title":"Adv Ther"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1016\/j.dsx.2022.102469","article-title":"Safety and efficacy of once weekly dipeptidyl-peptidase-4 inhibitor trelagliptin in type-2 diabetes: A meta-analysis","volume":"16","author":"Dutta D","year":"2022","unstructured":"Dutta D, Mohindra R, Surana V, Sharma M. Safety and efficacy of once weekly dipeptidyl-peptidase-4 inhibitor trelagliptin in type-2 diabetes: A meta-analysis. Diabetes Metab Syndr. 2022, 16:102469. 10.1016\/j.dsx.2022.102469","journal-title":"Diabetes Metab Syndr"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0157509","article-title":"Trelagliptin (SYR-472, Zafatek), novel once-weekly treatment for type 2 diabetes, inhibits dipeptidyl peptidase-4 (DPP-4) via a non-covalent mechanism","volume":"11","author":"Grimshaw CE","year":"2016","unstructured":"Grimshaw CE, Jennings A, Kamran R, et al.. Trelagliptin (SYR-472, Zafatek), novel once-weekly treatment for type 2 diabetes, inhibits dipeptidyl peptidase-4 (DPP-4) via a non-covalent mechanism. PLoS One. 2016, 11:e0157509. 10.1371\/journal.pone.0157509","journal-title":"PLoS One"},{"key":"ref16","unstructured":"SAS Enterprise Guide. SAS software, version 9.4. (2023). Accessed. January 31, 2024: https:\/\/support.sas.com\/software\/94\/."},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(14)70251-7","article-title":"Once-weekly trelagliptin versus daily alogliptin in Japanese patients with type 2 diabetes: A randomised, double-blind, phase 3, non-inferiority study","volume":"3","author":"Inagaki N","year":"2015","unstructured":"Inagaki N, Onouchi H, Maezawa H, et al.. Once-weekly trelagliptin versus daily alogliptin in Japanese patients with type 2 diabetes: A randomised, double-blind, phase 3, non-inferiority study. The lancet Diabetes & endocrinol. 2015, 3:191-7. 10.1016\/S2213-8587(14)70251-7","journal-title":"The lancet Diabetes & endocrinol"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-023-03571-8","article-title":"Socioeconomic factors associated with poor medication adherence in patients with type 2 diabetes","volume":"80","author":"Ekenberg M","year":"2024","unstructured":"Ekenberg M, Qvarnstr\u00f6m M, Sundstr\u00f6m A, Martinell M, Wettermark B. Socioeconomic factors associated with poor medication adherence in patients with type 2 diabetes. Eur J Clin Pharmacol. 2024, 80:53-63. 10.1007\/s00228-023-03571-8","journal-title":"Eur J Clin Pharmacol"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1177\/0145721707308407","article-title":"Medication taking and diabetes: A systematic review of the literature","volume":"33","author":"Odegard PS","year":"2007","unstructured":"Odegard PS, Capoccia K. Medication taking and diabetes: A systematic review of the literature. Diabetes Educ. 2007, 33:1014-29; discussion 1030-1. 10.1177\/0145721707308407","journal-title":"Diabetes Educ"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1111\/j.1745-7599.2004.tb00366.x","article-title":"Adherence to oral therapy for type 2 diabetes: Opportunities for enhancing glycemic control","volume":"16","author":"Bartels D","year":"2004","unstructured":"Bartels D. Adherence to oral therapy for type 2 diabetes: Opportunities for enhancing glycemic control. J Am Acad Nurse Pract. 2004, 16:8-16. 10.1111\/j.1745-7599.2004.tb00366.x","journal-title":"J Am Acad Nurse Pract"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.3810\/pgm.2011.01.2241","article-title":"Advantages of extended-release metformin in patients with type 2 diabetes mellitus","volume":"123","author":"Jabbour S","year":"2011","unstructured":"Jabbour S, Ziring B. Advantages of extended-release metformin in patients with type 2 diabetes mellitus. Postgrad Med. 2011, 123:15-23. 10.3810\/pgm.2011.01.2241","journal-title":"Postgrad Med"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1111\/j.1756-5391.2011.01158.x","article-title":"Effects and patient compliance of sustained-release versus immediate-release glipizides in patients with type 2 diabetes mellitus: a systematic review and meta-analysis","volume":"4","author":"Wang L","year":"2011","unstructured":"Wang L, Sun X, Du L, Yuan Q, Li H, Tian H, Li Y. Effects and patient compliance of sustained-release versus immediate-release glipizides in patients with type 2 diabetes mellitus: a systematic review and meta-analysis. J Evid Based Med. 2011, 4:232-41. 10.1111\/j.1756-5391.2011.01158.x","journal-title":"J Evid Based Med"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2006.12.011","article-title":"The relation between intermittent dosing and adherence: Preliminary insights","volume":"28","author":"Kruk ME","year":"2006","unstructured":"Kruk ME, Schwalbe N. The relation between intermittent dosing and adherence: Preliminary insights. Clin Ther. 2006, 28:1989-95. 10.1016\/j.clinthera.2006.12.011","journal-title":"Clin Ther"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.4065\/80.7.856","article-title":"Effect of dosing frequency on bisphosphonate medication adherence in a large longitudinal cohort of women","volume":"80","author":"Recker RR","year":"2005","unstructured":"Recker RR, Gallagher R, MacCosbe PE. Effect of dosing frequency on bisphosphonate medication adherence in a large longitudinal cohort of women. Mayo Clin Proc. 2005, 80:856-61. 10.4065\/80.7.856","journal-title":"Mayo Clin Proc"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(13)70149-9","article-title":"SYR-472, a novel once-weekly dipeptidyl peptidase-4 (DPP-4) inhibitor, in type 2 diabetes mellitus: A phase 2, randomised, double-blind, placebo-controlled trial","volume":"2","author":"Inagaki N","year":"2014","unstructured":"Inagaki N, Onouchi H, Sano H, Funao N, Kuroda S, Kaku K. SYR-472, a novel once-weekly dipeptidyl peptidase-4 (DPP-4) inhibitor, in type 2 diabetes mellitus: A phase 2, randomised, double-blind, placebo-controlled trial. Lancet Diabetes Endocrinol. 2014, 2:125-32. 10.1016\/S2213-8587(13)70149-9","journal-title":"Lancet Diabetes Endocrinol"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1111\/jdi.12499","article-title":"Long-term safety and efficacy of a novel once-weekly oral trelagliptin as monotherapy or in combination with an existing oral antidiabetic drug in patients with type\u00a02 diabetes mellitus: A 52-week open-label, phase\u00a03 study","volume":"7","author":"Inagaki N","year":"2016","unstructured":"Inagaki N, Sano H, Seki Y, Kuroda S, Kaku K. Long-term safety and efficacy of a novel once-weekly oral trelagliptin as monotherapy or in combination with an existing oral antidiabetic drug in patients with type\u00a02 diabetes mellitus: A 52-week open-label, phase\u00a03 study. J Diabetes Investig. 2016, 7:718-26. 10.1111\/jdi.12499","journal-title":"J Diabetes Investig"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/363061-efficacy-and-safety-of-once-weekly-trelagliptin-as-compared-to-twice-daily-vildagliptin-in-indian-patients-with-type-2-diabetes-mellitus-a-randomized-phase-3-non-inferiority-clinical-trial","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,2]],"date-time":"2025-06-02T08:54:23Z","timestamp":1748854463000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/363061-efficacy-and-safety-of-once-weekly-trelagliptin-as-compared-to-twice-daily-vildagliptin-in-indian-patients-with-type-2-diabetes-mellitus-a-randomized-phase-3-non-inferiority-clinical-trial"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,2]]},"references-count":26,"URL":"https:\/\/doi.org\/10.7759\/cureus.85219","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,6,2]]}}}